NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

TELA Bio, Inc. (TELA) Stock Analysis

TELA Bio, Inc. (TELA) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

TELA

$0.82

+$0.04 (+5.25%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TELA with… →

TELA Key Statistics

As of Sep 4, 2026
Trading
Open
$0.79
Previous Close
$0.78
Day's Range
0.79–0.84
52-Week Range
0.50–1.73
Volume
115.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.36
Valuation
Market Cap
$36.88M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.46
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.77
Financials (FY)
Revenue (FY)
$80.28M+15.84%
Net Income (FY)
−$38.83M
Profit marginThe share of revenue left as profit after all costs and taxes.
−51.53%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
44.89M
1-Year Return
−48.30%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
169.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TELA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−30.34%
2025−60.93%
2024−54.38%
2023−42.43%
2022−10.16%
2021−14.89%
2020+16.14%
2019 (partial year)−3.00%

As of September 4, 2026.

TELA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$80.28M−$38.83M−48.4%
2024$69.30M−$37.84M−54.6%
2023$58.45M−$46.66M−79.8%
2022$41.42M−$44.30M−106.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$80.28M$54.34M−$33.76M−$38.83M−48.4%
2024$69.30M$46.49M−$41.70M−$37.84M−54.6%
2023$58.45M$40.11M−$44.08M−$46.66M−79.8%
2022$41.42M$27.04M−$39.01M−$44.30M−106.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TELA Valuation vs Medical Devices Median

Median of 151 stocks
MetricTELAMedical Devices medianvs median
P/S ratio0.462.980.2x the median
Profit margin−51.53%−1.69%49.8 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values TELA Bio, Inc. (TELA) at $36.88M. The company sits in the Healthcare sector, in the Medical Devices industry. Headcount on file is 218.

Over the past 52 weeks the price has ranged from $0.50 to $1.73. TELA last closed at $0.82 on September 4, 2026. That is +$0.04 (+5.25%) against the previous close. The latest close sits 64.07% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $80.28M. Against the prior fiscal year total of $69.30M, that is a change of +15.84%. The same year closed with a net loss of $38.83M. Profit margin runs at −51.53%. That is 49.8 percentage points below the Medical Devices median of −1.69%. Earnings per share on a trailing basis come to −0.77.

Across the 4 fiscal years on file, revenue moves from $41.42M in 2022 to $80.28M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 0.46 times revenue. On price-to-sales that is 0.2 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 1.36. Annualized volatility over the trailing 6 years is 66.42%. The trailing one-year price return is −48.30%. Measured over 5 years, that is −42.45% a year compounded.

Growth & Income

The record shows no dividend for TELA.

Across the complete calendar years on file, 2020 returned +16.14% and 2025 returned −60.93%. Of the 6 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −30.34% year to date.

Peer Comparison

TELA Bio, Inc. (TELA) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TELA Bio, Inc. TELA $36.88M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. TELA Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About TELA Bio, Inc.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Visit website →